2. Signaling Pathways
  3. Immunology/Inflammation
  4. LAG-3

LAG-3

Lymphocyte activation gene-3; CD223

 

LAG-3 Related Products (11):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99156
    Relatlimab
    Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer.
    Relatlimab
  • HY-P99027
    Ieramilimab
    		98.23%
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules.
    Ieramilimab
  • HY-P99387
    TSR-033
    TSR-033 is a high affinity human IgG4 antibody targeting LAG-3 (lymphocyte activation gene-3), a co-receptor associated with impaired T cell function and often co-expressed with PD-1, that enhances T cell function and PD-1 blocking activity in vitro and in vivo. TSR-033 has anti-tumor activity.
    TSR-033
  • HY-P99933
    Eftilagimod alfa
    Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research.
    Eftilagimod alfa
  • HY-P99141
    Anti-Mouse LAG-3 Antibody (C9B7W)
    Anti-Mouse LAG-3 is an anti-mouse LAG-3 IgG1 antibody inhibitor derived from host Rat.
    Anti-Mouse LAG-3 Antibody (C9B7W)
  • HY-P990046
    Tuparstobart
    Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells.
    Tuparstobart
  • HY-P99573
    Tebotelimab
    		99.90%
    Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity.
    Tebotelimab
  • HY-P99617
    Fianlimab
    		99.04%
    Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity.
    Fianlimab
  • HY-P99613
    Favezelimab
    Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902).
    Favezelimab
  • HY-P99354
    Bavunalimab
    Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer.
    Bavunalimab
  • HY-P99736
    Miptenalimab
    Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II.
    Miptenalimab